Cargando…

Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia

PURPOSE: Information is lacking on prescribing of preventative cardiovascular pharmacotherapies for patients with non-ST elevation myocardial infarction (NSTEMI) in the Asian region. This study examined the prescribing rate of these pharmacotherapies, comparing NSTEMI to STEMI, and variations across...

Descripción completa

Detalles Bibliográficos
Autores principales: Venkatason, Padmaa, Zaharan, Nur Lisa, Ismail, Muhammad Dzafir, Wan Ahmad, Wan Azman, Mahmood Zuhdi, Ahmad Syadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999133/
https://www.ncbi.nlm.nih.gov/pubmed/29582106
http://dx.doi.org/10.1007/s00228-018-2451-3
_version_ 1783331368132935680
author Venkatason, Padmaa
Zaharan, Nur Lisa
Ismail, Muhammad Dzafir
Wan Ahmad, Wan Azman
Mahmood Zuhdi, Ahmad Syadi
author_facet Venkatason, Padmaa
Zaharan, Nur Lisa
Ismail, Muhammad Dzafir
Wan Ahmad, Wan Azman
Mahmood Zuhdi, Ahmad Syadi
author_sort Venkatason, Padmaa
collection PubMed
description PURPOSE: Information is lacking on prescribing of preventative cardiovascular pharmacotherapies for patients with non-ST elevation myocardial infarction (NSTEMI) in the Asian region. This study examined the prescribing rate of these pharmacotherapies, comparing NSTEMI to STEMI, and variations across demographics and clinical factors within the NSTEMI group in the multi-ethnic Malaysian population. METHODS: This is a retrospective analysis of the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome registry from year 2006 to 2013 (n = 30,873). On-discharge pharmacotherapies examined were aspirin, ADP-antagonists, statins, ACE-inhibitors, angiotensin-II-receptor blockers, and beta-blockers. Multivariate logistic regression was used to calculate adjusted odds ratio of receiving individual pharmacotherapies according to patients’ characteristics in NSTEMI patients (n = 11,390). RESULTS: Prescribing rates for cardiovascular pharmacotherapies had significantly increased especially for ADP-antagonists (76%) in NSTEMI patients. More than 85% were prescribed statins and antiplatelets but rates remained significantly lower compared to STEMI. Women and those over 65 years old were less likely to be prescribed these pharmacotherapies compared to men and younger NSTEMI patients. Chinese and Indians were more likely to receive selected pharmacotherapies compared to Malays (main ethnicity). Geographical variations were observed; East Malaysian (Malaysian Borneo) patients were less likely to receive these compared to Western region of Malaysian Peninsular. Underprescribing in patients with risk factors such as diabetes were observed with other co-morbidities influencing prescribing selectively. CONCLUSION: This study uncovers demographic and clinical variations in cardiovascular pharmacotherapies prescribing for NSTEMI. Concerted efforts by policy makers, specialty societies, and physicians are required focusing on elderly, women, Malays, East Malaysians, and high-risk patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-018-2451-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5999133
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-59991332018-06-28 Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia Venkatason, Padmaa Zaharan, Nur Lisa Ismail, Muhammad Dzafir Wan Ahmad, Wan Azman Mahmood Zuhdi, Ahmad Syadi Eur J Clin Pharmacol Pharmacoepidemiology and Prescription PURPOSE: Information is lacking on prescribing of preventative cardiovascular pharmacotherapies for patients with non-ST elevation myocardial infarction (NSTEMI) in the Asian region. This study examined the prescribing rate of these pharmacotherapies, comparing NSTEMI to STEMI, and variations across demographics and clinical factors within the NSTEMI group in the multi-ethnic Malaysian population. METHODS: This is a retrospective analysis of the Malaysian National Cardiovascular Disease Database-Acute Coronary Syndrome registry from year 2006 to 2013 (n = 30,873). On-discharge pharmacotherapies examined were aspirin, ADP-antagonists, statins, ACE-inhibitors, angiotensin-II-receptor blockers, and beta-blockers. Multivariate logistic regression was used to calculate adjusted odds ratio of receiving individual pharmacotherapies according to patients’ characteristics in NSTEMI patients (n = 11,390). RESULTS: Prescribing rates for cardiovascular pharmacotherapies had significantly increased especially for ADP-antagonists (76%) in NSTEMI patients. More than 85% were prescribed statins and antiplatelets but rates remained significantly lower compared to STEMI. Women and those over 65 years old were less likely to be prescribed these pharmacotherapies compared to men and younger NSTEMI patients. Chinese and Indians were more likely to receive selected pharmacotherapies compared to Malays (main ethnicity). Geographical variations were observed; East Malaysian (Malaysian Borneo) patients were less likely to receive these compared to Western region of Malaysian Peninsular. Underprescribing in patients with risk factors such as diabetes were observed with other co-morbidities influencing prescribing selectively. CONCLUSION: This study uncovers demographic and clinical variations in cardiovascular pharmacotherapies prescribing for NSTEMI. Concerted efforts by policy makers, specialty societies, and physicians are required focusing on elderly, women, Malays, East Malaysians, and high-risk patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00228-018-2451-3) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-03-26 2018 /pmc/articles/PMC5999133/ /pubmed/29582106 http://dx.doi.org/10.1007/s00228-018-2451-3 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Pharmacoepidemiology and Prescription
Venkatason, Padmaa
Zaharan, Nur Lisa
Ismail, Muhammad Dzafir
Wan Ahmad, Wan Azman
Mahmood Zuhdi, Ahmad Syadi
Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title_full Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title_fullStr Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title_full_unstemmed Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title_short Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia
title_sort trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-st elevation myocardial infarction (nstemi) in malaysia
topic Pharmacoepidemiology and Prescription
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999133/
https://www.ncbi.nlm.nih.gov/pubmed/29582106
http://dx.doi.org/10.1007/s00228-018-2451-3
work_keys_str_mv AT venkatasonpadmaa trendsandvariationsintheprescribingofsecondarypreventativecardiovasculartherapiesfornonstelevationmyocardialinfarctionnstemiinmalaysia
AT zaharannurlisa trendsandvariationsintheprescribingofsecondarypreventativecardiovasculartherapiesfornonstelevationmyocardialinfarctionnstemiinmalaysia
AT ismailmuhammaddzafir trendsandvariationsintheprescribingofsecondarypreventativecardiovasculartherapiesfornonstelevationmyocardialinfarctionnstemiinmalaysia
AT wanahmadwanazman trendsandvariationsintheprescribingofsecondarypreventativecardiovasculartherapiesfornonstelevationmyocardialinfarctionnstemiinmalaysia
AT mahmoodzuhdiahmadsyadi trendsandvariationsintheprescribingofsecondarypreventativecardiovasculartherapiesfornonstelevationmyocardialinfarctionnstemiinmalaysia